AI assistant
Apimeds Pharmaceuticals US, Inc. — Director's Dealing 2025
Nov 14, 2025
34894_dirs_2025-11-13_481e5baf-0cfb-4548-9f74-909f6a2cb181.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Apimeds Pharmaceuticals US, Inc. (APUS)
CIK: 0001894525
Period of Report: 2025-11-11
Reporting Person: Koo Jakap (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-11 | Stock Option (right to buy) | $2.67 | A | 10000 | Acquired | 2035-11-11 | Common Stock, par value $0.01 per share (10000) | Direct |
Footnotes
F1: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's employment continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the Company's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full vest upon the occurrence of a Change in Control, as defined in the Plan.